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Aims: Bile acid sequestrants (BAS) and physical activity (RUN) decrease incidence of cardiovascular
events. Both treatments are often prescribed, yet it is not known whether their beneﬁcial effects are
additive. We assessed the effects of BAS treatment alone and in combination with RUN on cholesterol
metabolism, heart function and atherosclerotic lesion size in hypercholesterolemic mice.
Methods:Male Ldlr-deﬁcient mice remained either sedentary (CONTROL), were treated with Colesevelam
HCl (BAS), had access to a running wheel (RUN), or were exposed to BAS and RUN (BAS RUN). All groups
were fed a high cholesterol diet for 12 weeks. Then, feces, bile and plasma were collected. Atherosclerotic
lesion size was determined in the aortic arch and heart function by echocardiography.
Results: BAS RUN ran more than RUN (6.4  1.4 vs. 3.5  1.0 km/day, p < 0.05). BAS and BAS RUN dis-
played w3-fold reductions in plasma cholesterol levels (p < 0.001), w2.5-fold increases in fecal neutral
sterol (p < 0.001) and bile acid (p ¼ 0.01) outputs, decreases in biliary secretions of cholesterol (w6-fold,
p < 0.0001) and bile acids (w2-fold, p < 0.001) vs. CONTROL while no signiﬁcant effects were observed in
RUN. Compared to CONTROL, lesion size decreased by 78% in both BAS and BAS RUN, (p < 0.0001).
Conclusion: BAS reduce atherosclerosis in Ldlr-deﬁcient mice, coinciding with a switch from body
cholesterol accumulation to cholesterol loss. RUN slightly modulated atherosclerotic lesion formation but
the combination of BAS and RUN had no clear additive effects in this respect.
 2013 Elsevier Ireland Ltd. All rights reserved. Open access under the Elsevier OA license.1. Introduction
Cholesterol has a central role in the pathogenesis of athero-
sclerosis. Strategies that increase fecal cholesterol excretion as
neutral sterols or bile acids, i.e., accelerate whole body cholesterol
turnover, improve the pro-atherogenic state by modulating plasma
lipid content and thus represent attractive strategies in the
amelioration of atherosclerosis.
Conversion of cholesterol into bile acids quantitatively repre-
sents a major route of cholesterol removal from the body. Bile acidsenter for Liver, Digestive and
ngen, Hanzeplein 1, 9713 EZ
; fax: þ31 (0)50 3611746.
der the Elsevier OA license.are synthesized exclusively in the liver and enter the intestinal
lumen after a meal to stimulate solubilization and uptake of dietary
lipids and fat soluble vitamins [1]. About 95% of the bile acids is
reabsorbed from the terminal ileum, transported back to the liver
for resecretion into bile (enterohepatic circulation). Besides their
role in lipid uptake, bile acids have emerged as importantmetabolic
regulators of glucose, lipid and energy metabolism [2] all impli-
cated in the pathogenesis of atherosclerosis.
Bile acid sequestrants (BAS) have long been utilized for treat-
ment of hypercholesterolemia [3]. BAS are positively charged
indigestible resins. In the intestinal lumen BAS bind negatively
charged bile acids forming non-absorbable complexes, thus
increasing fecal bile acid excretion which subsequently stimulates
the liver to convert cholesterol into bile acids. A compensatory
increase in hepatic LDL receptor activity clears LDL-cholesterol
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[3,4]. Additionally, human studies have shown that colestipol and
cholestyramine, two older generation BAS [3], induced reductions
in total and LDL-cholesterol that were not only accompanied by
reductions in relative coronary heart disease death [5] but also by
increased regression and decreased progression in coronary artery
lesion [6e9]. Colesevelam HCL is a more recent BAS that was spe-
ciﬁcally engineered for more speciﬁcity [3]. However, its effect on
atherosclerosis in humans has not been reported so far.
Physical activity has long been known as a beneﬁcial strategy for
cardiovascular risk reduction [10e17]. We have recently shown that
voluntary wheel running enhances cholesterol turnover into bile
acids in healthy chow-fed mice [18] as well as in hypercholester-
olemic atherosclerotic mice [17]. Furthermore, the running-
induced increase in fecal bile acid secretion coincided with a
reduction in atherosclerotic lesion size development in hypercho-
lesterolemic mice [17], demonstrating that physical activity bene-
ﬁcially modulates atherosclerosis by enhancing cholesterol
turnover in mice. However, despite the recognized beneﬁts of
physical activity in the prevention and management of cardiovas-
cular diseases, regular physical activity programs are frequently
reported to be underutilized, adherence to these programs proofs
poor or engagement in physical activity is not frequent enough
[19,20]. Moreover, physical activity will not result in adequate im-
provements in individuals presenting with more aggressive car-
diovascular derangements. In these situations, pharmacological
intervention becomes necessary and is prescribed either alone or in
combination with physical activity.
Thus, the aim of this study was to evaluate the effects of BAS-
induced disruption of bile acid metabolism on parameters of
cholesterol metabolism, atherosclerosis development and param-
eters of heart function in hypercholesterolemic mice. Since phar-
macological intervention and lifestyle changes are often co-
prescribed in cardiovascular disease risk management we further
evaluated whether a combination treatment of BAS and voluntary
wheel running would result in additional beneﬁts to BAS treatment
alone.
2. Methods
All experiments were approved by the Animal Care and Use
Committee of the University of Groningen, The Netherlands. The
University of Groningen is accredited by AAALAC (Association for
Assessment and Accreditation of Laboratory Animal Care Interna-
tional) and follows the Public Health Service Policy for the Care and
Use of Laboratory Animals (Local University approval number:
5599C). Animal care was provided in accordance with the pro-
cedures outlined in the Guide for the Care and Use of Laboratory
Animals.
2.1. Animals, voluntary cage wheel exercise and BAS treatment
Seventy-four 5-week-old male LDLR-deﬁcient (B6.129S7-
Ldlrtm1Her/J) mice were purchased from Jackson Laboratory (Bar
Harbor, ME, USA). Upon arrival, mice were singly housed
(47  26  14.5 cm cage) in a temperature-controlled room with a
12:12 lightedark cycle and had access to standard pelleted labo-
ratory chow (RMH-B, ABDiets Woerden, the Netherlands). At 8
weeks of age, all mice were switched to a western diet (0.25%
cholesterol, 16% fat, Puriﬁed Western Diet, 4021.06, ABDiets,
Woerden, The Netherlands) and randomly selected to either of the
following treatment groups: Sedentary on western-type diet only
(CONTROL, n ¼ 17), BAS treatment (BAS, western diet supple-
mented with 2% (wt/wt) Colesevelam HCL (Daiichi Sankyo, Inc.,
Parsippany, NJ, USA, n ¼ 17)), western-type diet exposed to avoluntary running wheel (RUN, n ¼ 20) and BAS exposed to a
voluntary running wheel (BAS RUN, n ¼ 20). All treatments lasted
for 12 weeks, mice had ad libitum access to food and water
throughout the study.
The voluntary running wheel set-up utilized has previously
been described [21]. Brieﬂy, the cage of RUN mice was equipped
with a hamster-sized metal cage wheel with a diameter of 11 cm
which was ﬁtted with a cycle computer containing a digital mag-
netic counter (Art NO.: K-13-TL SET-P3-NL, Xiron, Netherlands).
Each morning, total distances ran were recorded. Once a week,
bodyweight and food intake were recorded. Exposing mice to a
voluntary running wheel for twoweeks has previously been shown
to result in cardiac and skeletal muscle adaptations consistent with
those of endurance exercise [21]. Six mice with access to a volun-
tary running wheel were excluded from all analyses because they
showed no running wheel activity.
2.2. Experimental procedures
To examine the effect of BAS treatment and the combination of
BAS and voluntary wheel running on cholesterol and bile acid
metabolism fecal, plasma, biliary, hepatic and intestinal parameters
were collected at the endpoint of the experiment after 12 weeks of
respective intervention when mice were 20 weeks of age and
analyzed as described in the Supplement.
2.3. Tissue collection
Mice were opened immediately after blood collection. The heart
was slowly perfused with PBS at physiological pressure. Then, the
liver was excised, weighed and snap frozen in liquid nitrogen. The
small intestine was excised, ﬂushed with ice cold PBS (4 C) and
divided into three sections of equal lengths and subsequently snap
frozen in liquid nitrogen. Lastly, the thoracic aorta was excised and
epididymidal fat pads were removed and weighed. Thoracic aorta,
liver and intestine were stored at 80 C for later analysis. Hearts
were ﬂushedwith PBS to remove the excess of blood before ﬁxation
in formaldehyde 1% (Formal-Fixx, Thermo Electron Corporation,
Pittsburgh, Pa.) for 24 h, cut in an angle eventually revealing the
aortic sinus and stored at 80 C embedded in OCT (Tissue-Tek
O.C.T., Sakura, Zoeterwoude, The Netherlands).
2.4. Determination of atherosclerotic lesion size and aortic
cholesterol content
Atherosclerotic lesion size was determined as described earlier.
In brief, surface lesion area in the aortic sinus was measured after
Oil Red O staining by computer-assisted image quantiﬁcation with
Leica QWin software (Leica Microsystems, Wetzlar, Germany). Im-
ages were captured with a Leica DFC420 video camera. At least 5
sections per mouse were examined for each staining.
2.5. Heart function
Under 2% isoﬂurane anesthesia and maintenance of body tem-
perature mice were subjected to transthoracal echocardiography
utilizing a Vivid 7 machine (GE Healthcare, Diegem, Belgium)
equipped with special rodent software and a 14 MHz transducer as
described [22]. Cardiac dimensions were measured using para-
sternal short-axis view and M-mode tracings to determine end-
diastolic and end-systolic LV internal diameter, posterior wall
thickness (LVPW), and interventricular septal thickness (IVS). Left
ventricular mass was calculated as described [23]: LV mass ¼ 1.05
([LVIDd þ LVPWd þ IVSd]3  [LVIDd]3) g. The cardiac output was
calculated by measuring the left ventricular outﬂow tract (LVOT)
Fig. 1. BAS treatment reduces atherosclerotic lesion size. (A) Representative morpho-
logical sections of aortic sinus stained with Oil Red Oil of CONTROL, RUN, BAS and BAS
RUN mice, (B) Quantiﬁcation of lesion size in aortic sinus of CONTROL (n ¼ 9), RUN
(n ¼ 9), BAS (n ¼ 10) and BAS RUN (n ¼ 7) mice at 12 weeks of intervention. *p < 0.05
vs. CONTROL.
Table 1
Cardiac function.
CONTROL RUN BAS BAS RUN
LV mass (mg) 95.2  16.5 96.3  24.7 88.4  17.2 86.1  15.4
% Fractional
shortening
43  4 43  3 45  4 47  5
Heart
rate (bpm)
443  49 415  56 395  41 417  26
Cardiac output
(ml/min)
31.7  4.7 28.5  5.0 29.4  4.9 28.5  5.8
Values represent mean SD at 12 weeks of running in CONTROL, RUN, BAS and BAS
RUN, (n ¼ 8 for each group), LV ¼ left ventricular, bpm ¼ beats per minute.
M. Meissner et al. / Atherosclerosis 228 (2013) 117e123 119diameter and measuring a PW doppler signal over the LVOT (using
the formula: LVOT radius 2 p (3.14) LVOT VTI Heart rate).
2.6. Statistics
Multiple group comparisonswere done by the KruskaleWallisH
test, followed by Posthoc Conover test, using BrightStat software
[24] unless stated otherwise. The Wilcoxon Signed Rank test was
utilized for Supplemental Figure 1, comparing each week to week 1
separately. All data are expressed asmeans SD. A P-value of<0.05
was accepted as statistically signiﬁcant.
For more extended description of Methods see Supplement.
3. Results
3.1. Effect of BAS treatment on morphometric parameters and
running wheel activity
Despite an increased food intake compared to control mice,
BAS-treated running and sedentary mice both displayed a w14%
decrease in bodyweight which was paralleled by a decrease in liverweights. (Table S1). All mice exposed to a voluntary running wheel
progressively ran less during the 12-week running wheel inter-
vention. While a daily average running distance of w10 km was
observed at the beginning of the experiment, it dropped to 6.4 km/
day in BAS-treated mice and to 3.5 km/day in non-BAS-treated
running mice (p < 0.05) (Supplemental Figure 1). Furthermore,
we observed a signiﬁcant decrease in running wheel activity in
non-BAS-treated mice compared to BAS-treated mice starting at 11
weeks of running wheel exposure (p < 0.05, Supplemental
Figure 1).
3.2. BAS treatment decreases atherosclerotic lesion size
development in LDLR-deﬁcient mice
Quantiﬁcation of atherosclerotic lesion size in aortic sinus
showed a 78% reduction in BAS-treated mice compared to CON-
TROL (Fig. 1). The combination treatment of BAS and voluntary
wheel exercise yielded no additional effects on reducing athero-
sclerotic lesion size. Running mice not treated with BAS, showed a
23% reduction in atherosclerotic lesion size compared to CONTROL.
Atherosclerosis can over time lead to hemodynamic impairments
in the heart and thus to acute myocardial events. Impairments in
cardiac function have previously been reported for 36-week-old
LDLR-deﬁcient mice fed a western diet [25,26]. Thus, we evaluated
whether the BAS-mediated reduction in atherosclerotic lesion size
would impact on cardiac function in the 20-week-old LDLR-
deﬁcient mice of this study. However, no differences were
observed in left ventricular mass, percent of fractional shortening,
heart rate or cardiac output upon BAS and combination treatment
(Table 1).
3.3. BAS treatment beneﬁcially affects lipid metabolism in LDLR-
deﬁcient mice
Elevated lipid levels are key in the development of atheroscle-
rosis. We evaluated the effect of BAS treatment alone and in com-
bination with voluntary wheel running on plasma lipid levels,
plasma lipoprotein proﬁles as well as on hepatic parameters
involved in lipoprotein and lipid metabolism. BAS-treated mice
displayed signiﬁcant reductions in plasma levels of total cholesterol
(2.8-fold), cholesterol-ester (2.5-fold), free cholesterol (3.7-fold)
and triglycerides (3.9-fold) compared to CONTROL (Table 2), while
no additional improvements were observed in the combination
treatment. Importantly, we found improved plasma lipoprotein
proﬁles with reduced levels of VLDL- and LDL-sized lipoproteins in
all BAS-treated mice compared to CONTROL (Figure S2).
Further beneﬁcial effects of BAS treatment were observed on
hepatic lipid storage. BAS-treated mice displayed 1.8-fold re-
ductions in hepatic triglyceride stores compared to control mice
(Table 2), which was paralleled by a 40% reduction in hepatic
expression of the lipogenic gene Srebp1c (Table 3). The combina-
tion treatment of BAS and voluntary wheel running led to further
reductions in hepatic triglyceride stores and hepatic Srebp1c levels
Table 2
Plasma and liver lipids.
CONTROL RUN BAS BAS RUN
Plasma lipids (mmol/L)
Total cholesterol 30.4  3.4 30.2  4.3 10.7  1.2* 12.5  3.0*
Free cholesterol 10.8  1.0 10.8  1.5 2.9  0.6* 3.8  1.4*
Cholesterol esters 19.6  2.4 19.4  2.9 7.8  0.7* 8.7  1.7*
Triglycerides 11.9  1.3 10.9  1.3 3.0  0.5* 3.3  1.2*
Liver lipids (nmol/mg liver)
Triglycerides 40.6  7.7 23.3  5.5* 23.4  3.4* 13.6  1.2*,y
Total cholesterol 18.0  3.3 21.1  4.0 8.2  0.8* 8.1  0.8*
Free cholesterol 8.2  0.7 8.2  0.7 5.6  0.4* 5.8  0.3*
Cholesterol-ester 10.0  3.1 13.0  3.4 2.6  0.5* 2.3  0.5*
Phospholipids 26.7  1.3 28.2  1.3* 26.1  3.1 27.1  1.3
Values represent mean SD at 12 weeks of running in CONTROL, RUN, BAS and BAS
RUN, (n ¼ 8 for each group). *p < 0.05 vs. CONTROL. yp < 0.05 vs. BAS.
Table 4
Parameters of bile acid and cholesterol metabolism.
CONTROL RUN BAS BAS RUN
Bile ﬂow
(ml/min/100 gBW)
5.47  0.90 6.00  0.49 4.86  0.62* 5.12  0.82
Bile acids
Bile (mmol/day/
100g BW)
302  32 361  151 136  53* 146  52*
Feces (mmol/day/
100 gBW)
9  2 13  5 40  4* 53  14*
Synthesis
(mmol/day/
100 gBW)
9  2 13  5 40  4* 53  14*
Reabsorption
(mmol/day/
100 gBW)
293  31 312  121 96  55* 93  61*
Absorption (%) 97  1 96  3 65  18* 59  20*
Feces (%) 3  1 4  3 35  18* 41  20*
Cholesterol
Dietary intake
(mmol/day/
100 gBW)
83  4 97  8* 135  7* 156  14*
Bile (mmol/day/
100 gBW)
3.25  0.40 2.69  1.17 0.58  0.54* 1.08  0.76*
Dietary cholesterol
balance
(mmol/day/
100 gBW)
21  6 17  5* 36  10* 22  14*
Feces (mmol/day/
100 gBW)
62  8 79  8 171  12* 178  19*
This table represents measured and calculated values of ﬂuxes involved in the
enterohepatic system and parameters of cholesterol metabolism Values for bile acid
synthesis were assumed to equal the measured values for bile acids excreted via the
feces. Daily bile acid reabsorption was calculated by the difference in measured bile
acids secreted in the bile and feces. Dietary cholesterol balancewas calculated by the
difference between dietary cholesterol intake and fecal cholesterol excretion.
Values represent mean  SD at 12 weeks of interventions for CONTROL (n ¼ 6),
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displayed reductions in hepatic total cholesterol (2.2-fold), free
cholesterol (1.5-fold) and cholesterol-ester contents (3.8-fold)
compared to control mice. Despite the BAS-induced decrease in
hepatic cholesterol stores, we found increased hepatic levels of
Hmgcr (4.3-fold induction), which encodes the rate-limiting
enzyme in cholesterol biosynthesis, and Srebp2 (2-fold induction),
a protein implicated in control of cholesterol synthesis upon
cellular cholesterol depletion, in BAS-treated mice (Table 3).
Collectively, these data show that BAS provokes favorable changes
in lipid metabolism. To investigate whether the decrease in TG
stores induced on BAS treatment may have been caused by an
increased rate of FFA oxidation in muscle we have determined
mRNA expression levels of Cpt1 and2; Mcad and Ppara and g, no
changes were observed (data not shown).Table 3
Hepatic and intestinal genes of cholesterol and bile acid metabolism.
CONTROL RUN BAS BAS RUN
Liver
lipogenesis
Srebf1 1.0  0.2 0.7  0.2* 0.6  0.1* 0.5  0.1*,y
Cholesterol synthesis
Hmgcr 1.0  0.3 0.6  0.2* 4.3  1.0* 5.0  1.0*
Srebf2 1.0  0.1 0.9  0.2 2.0  0.3* 1.9  0.2*
Cholesterol excretion
Abcg5 1.0  0.2 0.9  0.2 0.8  0.1* 0.7  0.2*
Abcg8 1.0  0.2 1.0  0.3 0.9  0.3 0.8  0.2
Bile acid metabolism
Cyp7a1 1.0  0.6 0.7  0.4 3.8  1.6* 5.3  2.0*
Cyp8b1 1.0  0.2 0.8  0.2 2.1  0.4* 2.1  0.3*
Cyp27a1 1.0  0.2 0.9  0.2 1.3  0.2* 1.3  0.2*
Abcb11 (Bsep) 1.0  0.1 1.0  0.2 1.2  0.2 1.2  0.1*
Intestine
Cholesterol metabolism
Jejunal Abcg5 1.0  0.2 1.3  0.2 0.7  0.1* 0.7  0.2*
Jejunal Abcg8 1.0  0.3 1.3  0.2 0.6  0.1* 0.6  0.2*
Jejunal Abca1 1.0  0.2 0.8  0.2 0.3  0.1* 0.3  0.1*
Bile acid metabolism
Ileal slc10a2 (Asbt) 1.0  0.4 1.0  0.4 2.6  0.9* 2.3  0.4*
Ileal Fabp6 (Ibabp) 1.0  0.3 1.1  0.2 0.6  0.1* 0.6  0.1*
Ileal Fgf15 1.0  0.5 1.8  0.9 0.02  0.01* 0.02  0.02*
Hepatic and intestinal mRNA expression levels for sterol regulatory element-
binding protein 1 and 2 (Srepbf1/f2), 3-hydroxy-3-methylglutaryl-Coenzyme A
reductase (Hmgcr), ATP-binding cassette transporter g5 (Abcg5) and G8 (Abcg8),
cholesterol 7 alpha-hydroxylase (Cyp7a1), sterol 12-alpha-hydroxylase (Cyp8b1),
sterol 27-hydroxylase (Cyp27a1), bile salt export pump (Abcb11, Bsep), ATP-binding
cassette transporter A1 (Abca1), apical sodium-dependent bile acid transporter
(Slc10a2, Asbt), ileal bile acid-binding protein (Fabp6, Ibabp), ﬁbroblast growth
factor 15 (Fgf15) in CONTROL (n ¼ 8), RUN (n ¼ 8), BAS (n ¼ 8) and BAS RUN (n¼ 8);
Hepatic values are relative to b-actin, Intestinal values are relative to cyclophyllin
and Rplp0 (36b4) all values represent mean SD. *p< 0.05 vs. CONTROL. yp<0.05
vs. BAS.
RUN (n ¼ 8), BAS (n ¼ 8) and BAS RUN (n ¼ 8); *p < 0,05 vs. CONTROL.3.4. Effects of BAS treatment on sterol metabolism
Next, we assessed whether the BAS-induced beneﬁcial changes
in atherosclerotic lesion size and the improvements in plasma and
hepatic lipid levels were accompanied by BAS-induced modulation
of cholesterol and bile acid metabolism.3.5. BAS treatment increased fecal sterol output in LDLR-deﬁcient
mice
BAS-treated mice had signiﬁcantly higher neutral sterol and bile
acid excretions (2.3-fold and 4.2-fold, respectively; Table 4). As fecal
bile acid excretion is reﬂective of de novo synthesis, BAS-treated
mice displayed an increased de novo bile acid synthesis. This was
paralleled by a BAS-induced increase in hepatic expression of genes
encoding bile acid synthesizing enzymes; Cyp7a1, Cyp8b1 and
Cyp27a1 (Table 3) and by decreased ileal expression of ﬁbroblast
growth factor 15 (Fgf15), a gene which acts to inhibit bile acid
synthesis (Table 3).3.6. BAS treatment promotes a negative cholesterol balance
Because accumulation of excess cholesterol in vascular macro-
phages leads to formation of atherosclerotic plaques, we calculated
whole body cholesterol balances. The difference between dietary
cholesterol intake and fecal cholesterol excretion was positive in
non-BAS-treated mice (Table 4), demonstrating cholesterol accu-
mulation in the body. However, the cholesterol balance was
markedly decreased and became negative in BAS-treated mice,
even more in BAS-only-treated mice than in mice receiving the
combination treatment, showing that BAS-treated mice excreted
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probably compensated by an increase in de novo synthesis (Table 4).
3.7. BAS treatment decreased biliary sterol secretions
Subsequently, we assessed biliary parameters. Mice were sub-
jected to gallbladder cannulation for collection of hepatic bile at 12
weeks of interventions. BAS-treatedmice had an 11% decreased bile
ﬂow, and major reductions in biliary secretions of cholesterol (82%
decreased, Table 4), bile acids (55% decreased, Table 4) and phos-
pholipids (50% decreased, data not shown) compared to CONTROL.
The BAS-induced decrease in biliary cholesterol secretion was
paralleled by a modest decrease in expression of hepatic ATP-
binding cassette transporter Abcg5 and a slight, albeit not signiﬁ-
cant, reduction in Abcg8 (Table 3), which both act to transport
cholesterol across the canalicular membrane into the bile. BAS had
no effect on hepatic Abcb11 (Bsep) expression, which acts to
transport bile acids across the canalicular membrane (Table 3). The
combination treatment did not result in differential or stronger
effects on fecal and biliary parameters than BAS treatment alone. As
the fecal cholesterol loss was by far higher than the sum of biliary
and dietary cholesterol input upon BAS treatment, a non-
hepatobiliary cholesterol excretion pathway must have increased
considerably. This increase did not coincide with enhanced
expression of the cholesterol exporters Abcg5 and g8 because je-
junal expression actually decreased in the BAS-treated groups
(Table 3). Surprisingly, expression of the basolateral cholesterol
efﬂux mediator Abca1 decreased substantially as well (Table 3).
3.8. BAS treatment decreased bile acid reabsorption
From the fecal and biliary data we calculated other parameters
of in vivo bile acid and cholesterol turnover. As expected, daily
reabsorption of bile acids decreased upon BAS treatment (97  1%
in CONTROL vs. 65  18% in BAS and 59  20% in BAS RUN). A
compensatory upregulation of the ileal apical sodium-dependent
bile acid transporter (Slc10a2, Asbt), was observed. However,
expression of ileal bile acid binding protein (Fabp6, Ibabp), was
decreased with BAS treatment (Table 3).
4. Discussion
In the present study, we describe the effects of disrupting the
enterohepatic circulation of bile acids by Colesevelam HCL, a new
generation bile acid sequestrant (BAS) in an established mouse
model of atherosclerosis. Since lifestyle interventions, such as
physical activity, are often co-prescribed to pharmacological
intervention, we furthermore evaluated whether a combination
treatment of BAS and voluntary wheel running would yield addi-
tional beneﬁts over BAS treatment alone. Wewere able to show, for
the ﬁrst time, that treatment with Colesevelam HCL indeed pro-
vokes speciﬁc changes in cholesterol metabolism, speciﬁcally
switching from a positive to a negative cholesterol balance and
increasing cholesterol removal by a non-hepatobiliary route. These
favorable BAS-induced modulations translated into improved
plasma as well as liver lipid metabolism and ultimately into a
dramatic (78%) reduction in atherosclerotic lesion size develop-
ment in western-type diet fed, hypercholesterolemic LDLR-deﬁ-
cient mice. We also demonstrate that a combination treatment of
BAS and physical activity had no additional beneﬁts herein. Physical
exercise alone modestly reduced lesion size (23%). Surprisingly,
heart function was normal in all groups studied.
Our data demonstrate that under severe hypercholesterolemia as
in LDLR deﬁciency, BAS treatment clearly induces stronger metabolic
alterations that altogether lead to a much reduced progression ofatherosclerotic lesion size development compared to the running
treatment by itself. In general the changes in sterol metabolism
induced by the running intervention by itself where on averagew2-
to 3-fold less compared to the changes induced by the BAS treatment.
The combination treatment of BAS and running most likely had no
further beneﬁts compared to the BAS treatment alone, possibly
because BAS stimulated and exerted maximal possible change.
Intriguingly, running mice not treated with BAS ran w2-times
less than running mice treated with BAS during the last two
weeks of the experiment. To our surprise, they also ran signiﬁcantly
less than LDLR-deﬁcient mice fed a western-type diet in a previous
study [17]. Interestingly the decrease in atherosclerotic lesion size
was also less. To investigate whether the physical activity corre-
lated to the effect on lesion size we have plotted these parameters.
A signiﬁcant negative correlation was observed (Spearman
rs¼0.63, P¼ 0.044) for running wheel activity the area under the
curve for average km/day fromweek 1 to week 12 was determined.
A doseeresponse relationship between amount of physical activity
and cardiovascular risk reduction has previously been observed
[27,28] and the decrease in physical activity in running only mice
observed here is most likely the underlying factor for the discrep-
ancy between this and the previous study. We have no explanation
for the difference between the current and previous study because
all conditions were kept identical. There was also no difference in
inﬂammatory status of the mice as monitored by levels of plasma
cytokines such as IFNg, IL6/10 and TNFa (data not shown).
The differences in lesion size between groups did, in contrast to
our expectations, not associate with differences in cardiac function
in any group of the LDLR-deﬁcient mice. All echocardiographic
parameters were comparable to previously published reference
values for C57BL/6J and CD1 mice [22,29]. Previous studies showed
impaired heart function in 36-week-old LDLR-deﬁcient mice
[25,26]. Other reports suggested that LDLR-deﬁcient mice are prone
to cardiac dysfunction, even on normal diet [30] or on very short-
term (15 days) western-type diet [31]. We could not conﬁrm
these observations. It may be that our intervention was too short
lasting to elicit cardiac ischemia and subsequent damage. Thus, we
suspect that the control mice in the present study were too young
and atherosclerosis thereby not advanced enough for abnormalities
in heart function to manifest. Alternatively, although the LDLR-
deﬁcient mouse has resemblance with human coronary artery
disease, the sequence of events is rather different from man and
cardiac dysfunction and heart failure does not seem as prevalent in
this mouse model as in human disease. It thus remains to be
determined whether BAS treatment beneﬁts heart function inmore
advanced atherosclerosis.
Numerous studies have previously shown that BAS-induced
interruption of the enterohepatic circulation of bile acids leads to
an enhanced hepatic cholesterol demand for bile acid synthesis
[32e34].
Our data demonstrate a BAS-induced response for the increased
demand for cholesterol biosynthesis in several ways. First, we found
a more than w4-fold induction of the rate-limiting enzyme of
cholesterol synthesis, Hmgcr, in BAS-treated mice. This is inline
with the increased Hmgcr expression and fractional cholesterol
synthesis we recently reported in Colesevelam HCL-treated lean
and db/db mice on normal chow [32] but also supports an older
study showing that cholestyramine increased HmgCR activity
w6-fold in gallstone patients [33]. Secondly, we found BAS-induced
reductions in plasma LDL-sized lipoproteins paralleling earlier hu-
man studies using cholestyramine [34,35]. In contrast to results in
human studies, BAS treatment strongly reduced plasma triglyceride
as well as hepatic TG levels in the Ldlr mice on western-type diet.
Apparently, in this extreme model the pull on cholesterol meta-
bolism is adequate to largely normalize plasma lipoprotein levels.
M. Meissner et al. / Atherosclerosis 228 (2013) 117e123122Importantly, our data show that 12 weeks of Colesevelam HCL
treatment induces a new steady state in the enterohepatic ﬂux of
bile acids in hypercholesterolemic atherosclerotic mice. For
example within the model we studied, the calculated bile acid
reabsorption was reduced to 65% in BAS-treated mice compared to
control mice, which parallels the BAS-induced reduction in bile acid
reabsorption observed in lean and db/db mice [32]. Additionally,
while previous studies report no effects of BAS on biliary lipid se-
cretions [32,35], and bile acid pool size [32], we observed profound
reductions in biliary lipid secretion upon BAS here. These differ-
ences might be attributable to duration of treatment, diets or
mouse strain studied. Additionally, BAS treatment exerted sub-
stantial effects on the cholesterol balance. Under steady state
conditions the amount of cholesterol from dietary input and
endogenous synthesis equals fecal excretion. In this situation there
is no accumulation of cholesterol in the body. A positive cholesterol
balance leads to accumulation of excess cholesterol within the body
which can lead to formation of atherosclerotic plaque. The LDLR-
deﬁcient mouse has been long utilized as a murine model for
atherosclerosis due to its inability of hepatic LDL-lipoprotein up-
take which subsequently results in atherosclerosis. However, the
actual whole body cholesterol balance upon Ldlr deﬁciency has not
been reported. We show that BAS treatment is effectively inter-
fering with body accumulation of cholesterol leading to a sub-
stantial net loss of the sterol which coincided with a reduction in
atherosclerosis. Interestingly, BAS-treated mice displayed a sub-
stantial deﬁcit between fecal sterol excretion and the sum of di-
etary cholesterol intake and biliary cholesterol secretion. This
demonstrates that BAS treatment strongly enhances cholesterol
excretion from a non-hepatobiliary route. Since the origin of this
cholesterol was not determined in the present study we can not
differentiate whether this was caused by increased transintestinal
cholesterol excretion (TICE) or enhanced shedding of intestinal
epithelial cells.
In summary, the present study shows that disruption of the
enterohepatic circulation by BAS treatment substantially reduced
atherosclerotic lesion size in hypercholesterolemic mice which
coincided with profound changes in sterol metabolism, speciﬁcally
leading to a massive cholesterol loss. A combination treatment of
physical activity and BAS had no additive effects on atherosclerosis
development. Now that a new generation BAS compound has been
developed, with a much better safety and side effects proﬁle
[36,37], it may be imperative to re-evaluate the usefulness of BAS in
ﬁghting atherosclerosis in humans.
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